Loading
ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.
Catalyses the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively. Retinoate signalling is critical for the transcriptional control of many genes, for instance it is crucial for initiation of meiosis in both male and female. Recognises retinal as substrate, both in its free form and when bound to cellular retinol-binding protein.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Tretinoin.
In plain words · ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.
ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.
Catalyses the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively.
No product in this corpus aims at ALDH1A2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ALDH1A2: RNA tissue enhanced (endometrium 1 77 nTPM, fallopian tube 70 nTPM); blood lineage lineage enriched (granulocytes 33 nTPM); high antibody staining in 5 normal tissues; highest cancer staining colorectal cancer (6 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ALDH1A2 tissue; Open Targets ENSG00000128918 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Ono et al, Mol. Cell. Biol, 1998, "TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3". Source.
Sources: HGNC HGNC:15472 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O94788 (protein name, function text, keywords and locations (REST API)); CIViC gene ALDH1A2 (3 evidence items, 0 assertions, 2 variants; diseases: Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0))
Catalyses the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively. Retinoate signalling is critical for the transcriptional control of many genes, for instance it is crucial for initiation of meiosis in both male and female. Recognises retinal as substrate, both in its free form and when bound to cellular retinol-binding protein. Can metabolise octanal and decanal, but has only very low activity with benzaldehyde, acetaldehyde and propanal. Displays complete lack of activity with citral. Location: Cytoplasm (UniProt). Locus 15q21.3 (HGNC).
RNA: tissue enhanced (endometrium 1 77 nTPM, fallopian tube 70 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 33 nTPM).
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex.
RNA cancer enhanced: Kidney Chromophobe 33 pTPM.
Medium only: carcinoid, cervical cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ALDH1A2" OR ABSTRACT:"ALDH1A2" OR TITLE:"aldehyde dehydrogenase 1 family member A2" OR ABSTRACT:"aldehyde dehydrogenase 1 family member A2" OR TITLE:"Retinal dehydrogenase 2" OR ABSTRACT:"Retinal dehydrogenase 2" OR TITLE:"RALDH2" OR ABSTRACT:"RALDH2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ALDH1A2, not a curated reading list.